(Q26998884)

English

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management (English)

1 reference

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

S. Vincent Rajkumar

1

1 reference

language of work or name

1 reference

publication date

October 2014

1 reference

American Journal of Hematology

1 reference

89

1 reference

10

1 reference

999-1009

1 reference

Approach to the treatment of multiple myeloma: a clash of philosophies.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Pathogenesis of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A monoclonal gammopathy precedes multiple myeloma in most patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Solitary plasmacytoma of bone and extramedullary plasmacytoma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

POEMS syndrome: definitions and long-term outcome

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Diagnosis of Smoldering Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Myeloma bone disease: pathogenetic mechanisms and clinical assessment.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Identification of a primary target of thalidomide teratogenicity

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Treatment of myeloma: cure vs control

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Management of multiple myeloma: a systematic review and critical appraisal of published studies

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Clinical course of patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Redefining myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23810

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26998884&oldid=1743669187"